In light of those results, PPARγ agonists appear to becompelling drugs for the prevention of liver injury related to insulin resistance.PPARα could be involved in fibrogenesis through adiponectin activation, as thisadipokine could have antifibrogenic properties. The gene discussed is PPARG; the disease is Insulin resistance.